(Q43408121)

23 November 2017

title

Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

23 November 2017

main subject

1 reference

1 reference

1 reference

1 reference

Areana Diogo Nascimento

1

1 reference

23 November 2017

Lucia Alves Silva Lara

2

1 reference

23 November 2017

Ana Carolina Japur de Sá Rosa-e-Silva

3

1 reference

23 November 2017

Rui Alberto Ferriani

4

1 reference

23 November 2017

Rosana Maria Reis

5

1 reference

23 November 2017

publication date

30 November 2012

1 reference

Gynecological Endocrinology

23 November 2017

published in

1 reference

23 November 2017

volume

29

1 reference

23 November 2017

issue

3

1 reference

23 November 2017

page(s)

246-249

1 reference

The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Anti-Müllerian hormone as a predictor of IVF outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Serum anti-Mullerian hormone throughout the human menstrual cycle.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Follicle dynamics and anovulation in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Aberrant follicle development and anovulation in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.736563

10.3109/09513590.2012.736563

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference